Abstracts tagged "Inflammation"

Abstract Number: 1608 • ACR Convergence 2022
Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study
Huan Meng¹, Isaac Cheng², Byran P Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam², ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis driven by chronic inflammation. We have previously reported that achieving sustained disease activity score 28 (DAS28)…
Abstract Number: 1832 • ACR Convergence 2022
Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
Barbara Finck, Helen Tang, Kathy Jensen, Francesca Civoli and Suzanna Tatarewicz, Coherus BioSciences, Redwood City, CA
Background/Purpose: This study aimed to demonstrate that there were no clinically meaningful differences between adalimumab-aqvh, a US Food and Drug Administration–approved biosimilar, and adalimumab in…
Abstract Number: 2126 • ACR Convergence 2022
Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
Shawn Kwatra¹, Saakshi Khattri², Ahmad Amin³, Huzefa Photowala⁴, Ran Liu⁴, Byron Padilla⁵, Blair Kaplan⁴ and Dennis McGonagle⁶, ¹John Hopkins University, Baltimore, MD, ²Mount Sinai Medical Center, New York, NY, ³Northwestern Medicine Dermatology, Chicago, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a progressive condition with chronic inflammation and joint destruction impacting quality of life.1 Dactylitis and enthesitis are clinically relevant domains…
Abstract Number: 0055 • ACR Convergence 2022
Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice
Yue Peng¹, H. Mark Kenney², Karen Bentley³, Lianping Xing⁴, Christopher Ritchlin⁵ and Edward Schwarz¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Henrietta, NY, ³University of Rochester, Rochester, ⁴University of Rochester Medical Center, Webster, NY, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1). Mast cells (MCs) regulate lymphatic vessels by releasing inflammatory and vasoactive mediators (e.g. histamine) (2). Previous…
Abstract Number: 0548 • ACR Convergence 2022
Postural Orthostatic Tachycardia Syndrome, Small Fiber Neuropathy, and Systemic Inflammation: Are They Related?
Elizabeth Bettini, Carolyn Ramwell, Sangeeta Sule and Jeffery Moak, Children's National Hospital, Washington, DC
Background/Purpose: Postural Orthostatic Tachycardia Syndrome (POTS) is a dysautonomia associated with chronic autonomic and neuropathic symptoms, including pain in multiple body regions, paresthesia, fatigue, brain…
Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Joshua Reynolds¹, Chandra Mohan², Yaxi Li² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…
Abstract Number: 1151 • ACR Convergence 2022
Colonic Organoids to Study the Role of HLA-B27 in Gastrointestinal Epithelial Biology
Alec Furst¹, John Davis¹, Manuel Rodriguez¹, Kimberly Ogle¹, James T. Rosenbaum² and Tejpal Gill¹, ¹OHSU, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is defined clinically as inflammatory back pain along with peripheral arthritis, and extra-articular manifestations involving the eye, gut, and skin. Even…
Abstract Number: 1610 • ACR Convergence 2022
Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?
Solveig S. Groen¹, Signe Holm Nielsen², Anne-Christine Bay-Jensen², Mozhgan Rasti³, Darshini Ganatra³, Katerina Oikonomopoulou³ and Vinod Chandran⁴, ¹Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Inflammatory and degenerative processes in the joint tissues are hallmarks of patients with psoriatic arthritis (PsA). Here, proteases play a major role in remodeling…
Abstract Number: 1833 • ACR Convergence 2022
Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial
Hildrun Haibel¹, Joachim Sieper¹, Denis Poddubnyy², valeria Rios-Rodriguez³, Fabian Proft², Mikhail Protopopov⁴, Judith Rademacher⁴, Sabrina Igel⁵, Peter Martus⁶ and Christoph Stein⁵, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany, ⁶University Hospital Tübingen, Tübingen, Germany
Background/Purpose: The current standard of intraarticular therapy in patients with inflammatory arthritis (e.g. rheumatoid arthritis; RA) or inflammatory exacerbations of osteoarthritis (OA) is the injection…
Abstract Number: 2143 • ACR Convergence 2022
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Georg Pongratz², Luca Navarini³, Rodrigo Garcia Salinas⁴, Tianming Gao⁵, Marie-Claude Laliberté⁶, Ralph Lippe⁷ and Philip J Mease⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, ³Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, ⁴Hospital Italiano de La Plata, La Plata, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Québec, QC, Canada, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…
Abstract Number: 0133 • ACR Convergence 2022
Retention Rate of Targeted Therapies in Erdheim-Chester Disease
Corrado Campochiaro¹, alessandro tomelleri¹, Francesco Pegoraro², Giovanni Galardi³, Nicola Farina⁴, Martina Mazzariol⁵, Francesco Catamerò⁶, Giacomo De Luca⁴, Giulio Cavalli⁴, Augusto Vaglio⁷ and Lorenzo Dagna⁸, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ²Department of Health Sciences, University of Florence, Firenze, Italy, ³Department of Health Sciences, University of Florence, Florence, Italy, ⁴IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Milano, Italy, ⁵University of Turin, Torino, Italy, ⁶Vita-Salute San Raffaele University, Milano, Italy, ⁷Azienda Ospedaliero Universitaria Meyer, Parna, Italy, ⁸IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Italy
Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last…
Abstract Number: 0557 • ACR Convergence 2022
VEXAS Syndrome Is Characterized by Blood and Tissues Inflammasome Pathway Activation and Monocyte Dysregulation
Benjamin Terrier¹, Celine Posseme², Marie Temple³, Aurélien Corneau⁴, Francesco Carbone⁵, Eugénie Duroyon³, camille Gobeaux³, Estibaliz Lazaro⁶, Roderau Outh⁷, Guillaume Le Guenno⁸, Francois Lifermann⁹, Marie Berleur¹⁰, Thierry Weitten¹¹, Vivien Guillotin¹², Cédric Lenormand¹³, Hang-Korng Ea¹⁴, Mickael Ménager⁵, Darragh Duffy² and Olivier Kosmider³, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Institut Pasteur, Paris, France, ³Cochin Hospital, Paris, France, ⁴Pitié Salpêtrière Hospital, Paris, France, ⁵Institut Imagine, Paris, France, ⁶Bordeaux Hospital University, Bordeaux, France, ⁷CH, Perpignan, France, ⁸CHU, Clermont-Ferrand, France, ⁹Dax Hospital, Dax, France, ¹⁰CH, Versailles, France, ¹¹CHIGAS, Gap, France, ¹²CHU Bordeaux, Bordeaux, France, ¹³CHRU, Strasbourg, France, ¹⁴Lariboisière Hospital, Paris, France
Background/Purpose: Acquired mutations in the UBA1 gene, occurring in myeloid cells and resulting in expression of a catalytically impaired isoform of the enzyme E1, were…
Abstract Number: 0693 • ACR Convergence 2022
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
Naveen Kumar S K¹, Claire Hoy¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Kaitlyn Sabb¹, Christine Rysenga¹, Jacqueline Madison¹, Yu Zuo¹ and Jason S Knight³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: By converting extracellular ATP into homeostatic adenosine, the ectonucleotidases CD39 (ATP to AMP) and CD73 (AMP to adenosine) dictate extracellular purinergic gradients and as…
Abstract Number: 1154 • ACR Convergence 2022
Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells
Aneta Pekčcová¹, Kristýna Bubová², Monika Gregova³, Šárka Forejtová², Jana Hořínková², Markéta Hušáková², Michal Tomcik⁴, Jindřiška Gatterová², Jiří Vencovský⁵, Karel Pavelka⁶, Ladislav Šenolt⁵ and Jiří Baloun², ¹Institue of Rheumatology, Prague, Prague, Czech Republic, ²Institue of Rheumatology, Prague, Czech Republic, ³Institue of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic
Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs, which are essential for correct gene expression. The dysregulation in miRNA expression is accompanied by various diseases and…
Abstract Number: 1614 • ACR Convergence 2022
Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Torsten Diekhoff⁵, Mikhail Protopopov⁶, Elisabeth Altmaier⁷, Fabiana Ganz⁸ and Robert Inman⁹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ⁵Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁸AbbVie, Inc., Luzern, Switzerland, ⁹University Health Network, Toronto, ON, Canada
Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].